Challenges and advances in clinical applications of mesenchymal stromal cells

MSCs were immune privileged due to the low expression of MHC-I and HLA-I, and no expression of HLA-II or costimulatory factors such as CD40, CD80 and CD86. MSCs can be transplanted as allogeneic cells with a low risk of rejection. Generally, the original MSCs are believed to have low immunogenicity [16]. Most MSC products are manufactured by amplifying a small number of cells obtained from donors, which can increase MSC immunogenicity caused by inappropriate processes and culture conditions. After MSCs infusion, the in vivo inflammatory molecules in turn increase MSC immunogenicity and further decrease MSCs viability and differentiation capacity, particularly when administrating xenogenic MSCs including human MSCs in animal models [17]. Although the primary immunogenicity of MSCs derived from in vitro experiments might be minimal, the secondary immunogenicity induced by in vivo positive feedback loops can cause the absence of efficacy reported in most clinical trials.

Studies have shown that inflammatory molecules (such as interferon-γ), increased cell density, and/or serum deprivation can induce high expression of MHC-II in MSCs, while TGF-β suppresses MHC-II expression [18]. The immune compatibility between donors and recipients is the key to reduce the risk of rejection in the event of long-term treatments with repeated infusions, in conditions requiring promotion of transplanted bone marrow integration, or post-renal transplantation rejection treatments [19]. It has been reported that repeated intra-articular injection of allogeneic MSCs is more likely to cause an adverse reaction than autologous cells when administered in the same manner [20]. The same observations were reported in horses treated with intracellular xenogen-contaminated autologous MSCs (such as FBS) or non-xenogen-contaminated allogeneic MSCs [21].

MSCs of high quality is the first step to ensure the safety and efficacy in clinical trials. Understanding the molecular and cellular mechanisms underlying the immune incompatibility of MSCs will help to improve the manufacture of MSC products.

MSCs have mesodermal lineage differentiation potential and the potential to regulate tissue regeneration by mediating tissue and organ repair, as well as replacing damaged cells [22]. Different tissue-derived MSCs exhibit tendencies to differentiate into different end-stage lineage cells [23, 24], and such regeneration and differentiation contribute to distinctive clinical efficacy.

Several laboratories have analyzed the proteome modifications associated with MSCs differentiation [25, 26]. They indicated that ‘‘stemness’’ genes were highly expressed in undifferentiated and de-differentiated MSCs [27, 28]. These highly stemness-related gene clusters in MSCs have been found to be mainly involved in the proliferation, differentiation, and migration [29]. When MSCs differentiated into osteoblasts, chondrocytes, and adipocytes, expressions of these genes significantly decreased, underlining their unique characteristics. Table 2 lists typical stemness genes of MSCs.

Serial passaging in long-term culture could negatively affect the expression of stemness genes [48, 49]. A previous study indicated that CD13, CD29, CD44, CD73, CD90, CD105, and CD106 in MSCs are down-regulated during culture expansion compared to MSCs in the stromal fraction [50]. The senescence-related proteins p53, p21, and p16 expressed under different conditions [51]. Rene et al. reported that after short-term in vitro culture, wild-type MSCs became senescent, and p21(−/−)p53(+/+) MSCs showed an elevated spontaneous apoptosis rate but no sign of tumoral transformation [52]. On the other hand, Mclean et al. discovered cancer-associated MSCs (CA-MSCs), which are determined by the expression of CD44, CD73, and CD90, exhibited the upregulation of the TGF-β superfamily/bone morphogenetic protein (BMP) family [53], and MSCs harbored the potential to differentiate into cancer-associated fibroblasts (CAFs) at latter passages [54‐57]. The malignant phenotypes of MSCs associated with CAFs could express Meflin, which is also a marker of MSCs maintaining their undifferentiated state [57‐59].

To provide sufficient MSCs for clinical trials, MSCs need to be amplified in a large scale, which will inevitably face the issue of MSCs senescence and subsequent modifications of gene expressions [60]. Therefore, the long-term culture of MSCs often results in decreased proliferation and differentiation capacities and shortened life expectancy [61]. A standardized manufacturing process is essential for the success of clinical trials. Though the above molecules have been found to mediate the stemness of MSCs and regulate their differentiation, it remains challenging to control the fate of MSCs in a complex in vivo environment.

Heterogeneity of MSCs is determined by multiple factors including but not limited to donors and tissue sources, cell populations, culture conditions, cell isolation techniques, cryoprotective and thawing protocols [62‐64] (Fig. 3).

MSCs were defined as adherent cells with a spindle-shaped morphology in standard culture conditions according to the minimal criteria developed by the International Society of Cell Therapy in 2006 [65]. They were characterized by the following features: (1) expression of CD105, CD73, and CD90, but no expression of CD45, CD34, CD14 or CD11b, CD79a, CD19, or HLA-DR; (2) capacity to differentiate into osteoblasts, adipocytes, and chondroblasts in vitro. However, these criteria were insufficient to define MSCs as variations exist at multiple levels. First, MSCs from different donors have distinct functions due to differences in age, health condition, and other individual characteristics. Second, MSCs from different tissues ranging from adipose tissue to bone marrow could be distinct in terms of surface markers and differentiation capacities. This variation probably results from different biological, chemical, and mechanical stresses in stem cell niches, though the culture conditions are similar in vitro. Moreover, MSCs form clones, and cell heterogeneity exists both inter-clonally and intra-clonally. Extracellular matrix genes and osteogenic transcription factor-related genes show increased expression in highly osteogenic clones compared to poor osteogenic clones. Cell morphology and differentiation ability within one clone can also be remarkably different. For instance, cells located at the outer periphery express higher levels of genes related to cell proliferation (MKI67 and PODXL), while extracellular matrix genes (VCAM1) tend to be expressed in interior MSCs [66].

To identify specific cell subsets in heterogeneous MSCs, researchers have been continuously exploring characteristic cell surface markers and molecular signatures. Single cell-derived colony with rapidly dividing cells shows high colony-forming efficiency. STRO-1, CD146, and CD271 have been identified as cell surface markers for this subset [67]. However, cell subsets sharing similar surface markers would exhibit different chondrogenic differentiation capacities even under the same culture conditions [68]. RNA sequencing and microarray analysis have showed transcriptional signals predicting differentiation potential. Osterix and distal-less homeobox5 are the main transcription factors involved in osteoblast differentiation, while peroxisome proliferator-activated receptor gamma (PPAR-γ) and CCAAT/enhancer-binding protein alpha are associated with adipogenic potential [69]. In addition, MSCs with specific surface markers of differentiation potential may present various physiological functions [70]. For example, CD105 + MSCs exhibited myogenic potential assisting the repairment of the infarcted myocardium [71], while CD106 + MSCs showed enhanced multipotency and immunosuppressive ability [72]. Increasing evidence shows that MSCs comprise multiple subsets with specific surface markers. More work is needed to define these subpopulations based on biomarkers and biological functions.

The therapeutic efficacy of MSCs is highly dependent on their in vivo migration and homing capacities. The migrating direction is determined by chemokine receptors expressed on MSCs and chemokines in tissues [73]. Freshly isolated MSCs have a good homing effect, which is decreased after somatic expansion. For example, the chemokine receptor CXCR4 is highly expressed on primary bone marrow MSCs, but gradually lost with passages, resulting in the less recognition of its ligand CXCL12 (also known as SDF-1α) [74, 75]. Together, the primary MSCs are expected to have a better therapeutic efficacy due to more potent migration capacity.

However, the expression profile of chemokines in damaged tissues is often not compatible with that of receptors on MSCs. For instance, CXCL1, CXCL2 and CCL7 increased in infarcted myocardium, while expression of corresponding receptors (CCR1 and CXCR2) on MSCs was very low, resulting in low efficiency in the migration of MSCs to infarct sites [76]. To improve the migration rate, MSCs are genetically modified to express specific chemokine receptors [73]. For example, CCR7-modified MSCs efficiently migrated to secondary lymphoid organs and demonstrated significant clinical efficacy in the GVHD mouse model [77, 78]. CXCR5-modified MSCs migrated to the damaged sites by binding to CXCL13, which was highly expressed in damaged tissues [79]. Taken together, genetically modified MSCs are an independent treatment entity and could be used as targeted therapy.

The delivery of MSCs emerges as a prerequisite to the unfoldment of their full therapeutic potential. Different delivery routes could affect cell homing, survival, and paracrine function. Systemic delivery is considered a reasonable approach. However, the reported effect in terms of homing rate, survival rate, and maintenance of cellular function was modest and transient [80] for reasons including poor migration rate from vessels to tissues and high retention rate in the liver, lungs, and spleen [81]. In contrast to intravenous delivery, intra-tissue or intra-organ delivery showed higher delivery retention and efficiency, as evidenced by a large body of studies [82]. However, clustering of MSCs and occlusions in microvasculature has been reported in some disease models such as myocardial infarction [83]. Walczak et al. reported that only cells with a diameter between 20 and 50 μm could avoid intracerebral entrapment [84]. Therefore, to maximize therapeutic efficacy, both the migratory capacity of MSCs and appropriate delivery methods should be considered.

Theoretically, MSCs can be expanded in vitro in traditional culture plates and flasks to any amount that meets experimental purpose. However, with prolonged culture duration and increased passage numbers, MSCs reach the Hayflick limit, exhibiting a marked decrease in proliferation with a transformation in morphology from a thin spindle shape to a flattened square shape. The cell density seeded in the culture containers also plays a role in the senescence of MSCs. Neuhuber et al. found the optimal cell growth of rat MSCs at 200 cells per cm² compared with 20 cells or 2000 cells per cm² [85]. In other studies, a relatively low density (~ 1.5–200 cells per cm²) was suggested to support better proliferation [86]. Alterations in autocrine secretion and contact inhibition may contribute to the slow growth at high density.

Large-scale expansion in 2D plates over long term also impacts stem cell characteristics of MSCs. According to Zhao et al., hUC-MSCs at various passages have multiple mutation spectra on signatures and functions, and cells at high passage showed declined therapeutic effect in aGVHD mouse model [87]. It has been shown that chondrogenic differentiation of MSCs in 2D culture is less efficient than that of MSCs in 3D culture [88]. Therefore, 3D expansion of MSCs was developed to prevent phenotypic changes caused by monolayers, where a broad and flattened morphology upon passaging was well preserved.

Moreover, MSCs have shown the capacity to differentiate into numerous cell types such as neural cells, hepatocyte-like cells, and pancreatic islet-like cells [89, 90]. The transient differentiation of MSCs into neural precursor-like cells may experience de-differentiation during extended culture [91]. Therefore, in vitro induction is often insufficient to yield pure functionally competent cells.

Taken together, developing the technique that can produce a huge number of cells rapidly and cost-effectively with guaranteed cell quality is paramount for the clinical progress of MSCs.

The secretion of cytoprotective factors by MSCs was first reported by Gnecchi and colleagues. They observed that Akt-MSCs (MSCs overexpressing Akt) prevented ventricular remodeling and improved the heart function following surgical myocardial infarction (MI). Since cell transplantation and myogenic pathways would be ineffective over such a brief interval, a new mechanism was proposed that the injected MSCs might act through releasing trophic factors that contribute to myocardial protection following an ischemic insult. This hypothesis was then confirmed by evident improvements in cardiac performance following injection of conditioned medium (CM) collected from hypoxic Akt-MSCs into an induced MI model, which protected ventricular cardiomyocytes with less apoptosis when subjected to a hypoxic condition [92].

In 2007, Dai et al. observed that MSCs-CM had a similar, albeit less intense, effect of MSCs in myocardial infarction, indicating that at least part of the effect observed following MSCs injection could be attributed to soluble factors [93]. In the context of neuronal damage, it has been established that the presence of BDNF, GDNF, NGF, and IGF in the MSCs secretome is necessary for the neuronal survival in vitro and in vivo [94, 95]. MSCs-CM has demonstrated therapeutic efficacy in some other disease models including chronic kidney disease, certain lung, and liver diseases [96, 97].

The paracrine effects of MSCs as an initial mechanism of action inspired further biological analysis of MSCs secretome [98]. Subsequent studies found more paracrine effectors, including soluble cytokines, growth factors, hormones, miRNAs, or lncRNAs that targeting a variety of cells such as immune cells and injured tissue cells [99]. In addition, the paracrine effectors could be loaded in extracellular vesicles (EVs) and exerted long-term effects [100]. In accordance, many studies have shown that MSC-derived EVs retain the biological activity of parental MSCs. It has been demonstrated that EVs showed a similar therapeutic effect as MSCs in selected animal models [101]. However, different studies found various effective components of MSCs in specific animal models and human diseases, and the interactions and functional differences between effectors remain elusive. Therefore, novel in-depth analytical techniques and platforms are warranted to investigate the MSCs secretome in the future.

Biomaterials for delivering MSCs have been extensively investigated. These materials showed advantages in offering a scaffold for the adherence and survival of MSCs, as well as preserving the functional components MSCs secreted, thus elongating the effective durations in clinical treatment. However, the implantation of biomaterials could induce the foreign-body responses (FBR) in the host immune system, which can potentially result in fibrosis and failure of the implantation. Therefore, biomaterials suitable for MSCs were constructed to ameliorate the FBR and subsequent fibrotic encapsulation [102]. For example, loading MSCs with small-molecule encapsulating microparticles (MPs) can boost the duration of the products. MPs are composed of biocompatible materials that can be therapeutically tuned according to their composition, polymer molecular weight, drug loading, and release capacities [103]. MSCs loaded with degradable budesonide-containing MPs exhibited fourfold increase in IDO activity in vitro compared to MSCs without being pre-treated with budesonide [104]. This led to a twofold improvement in the suppression of peripheral blood mononuclear cells (PBMCs) activation following IFN-γ stimulation [105].

MSCs are typically delivered to a graft site using a decellularized extracellular matrix (ECM) scaffold. The advent of synthetic polymers has revolutionized tissue engineering. These polymers are highly tunable, homogenous, and cell-free materials and have a high batch-to-batch consistency taking the form of porous hydrogels, sponges, plates, or membranes [106, 107]. However, their unique properties could exert different influences on MSCs function. Table 3 summarizes the influence of biomaterials properties on the function of MSCs, including dimensionality, stiffness, topographical cues, surface chemistry, and microstructure of biomaterials.

Given current manufacture of MSCs cannot meet the requirement for clinical trials in terms of production scale, the alternative is to boost the function of limited cells through priming MSCs. Priming has also been referred to as licensing or preconditioning, which is a concept commonly used in the field of immunology, and it has been adapted to the scope of stem cells [144, 145]. One of the commonly used strategies is priming MSCs with pro-inflammatory mediators, including IFN-γ, TNF-α, IL-1α, and IL-1β, and more priming approaches are being proposed to improve the function, survival, and therapeutic efficacy of MSCs [146, 147]. The priming approaches could be divided into three categories based on the stimulations: (a) MSCs priming with small molecules, (b) MSCs priming with hypoxia, (c) MSCs priming with biomaterials. Table 6 summarizes some representative priming MSCs.

“Priming” MSCs resulted in exogenously boosted therapeutic function in comparison with original state. Several “primed” MSC products have been applied clinically, with the most notable being NurOwn from Brainstorm Cell Therapeutics Company. NurOwn boosted the expression of multiple neurotrophic factors (NTFs) including GDNF, BDNF, VEGF, and HGF [173]. When administered to patients with neurodegenerative diseases, NurOwn delivered multiple NTFs as well as the immunomodulatory components secreted by MSCs. This combination demonstrated impressive therapeutic efficacy in a phase 2 clinical trial (NCT02017912), in which ALS patients got reduced ALS progression 24 months after NurOwn infusion compared to the controls [174]. So the indication of NurOwn has been expanded to include multiple sclerosis.

However, priming approaches of MSCs still have many limitations in clinical translation, such as induction of immunogenicity, high costs, variable effects, and lack of good manufacturing practices (GMP) suitable for clinical application [175]. Moreover, the long-term effect of priming MSCs has not been evaluated yet. Further studies are needed to evaluate (1) the effects of different priming approaches in clinic; (2) the best sources for MSCs isolation; (3) the epigenetic modifications, immunogenicity, and tumorigenicity of primed and non-primed MSCs; and (4) the appropriate GMP standards for quality control of MSC products, including quality of cryopreserved primed-MSCs at different passages.

The “secretome” of MSCs, including secretory proteins such as growth factors, cytokines, and chemokines and EVs such as microvesicles (MVs; 100–1000 nm diameter) and exosomes (40–150 nm diameter), has been shown to exhibit many of the therapeutic properties of MSCs. For example, MSC-derived EVs have demonstrated similar or even superior therapeutic capacity for autoimmune diseases and neurodegenerative disorders compared with their parental MSCs [176, 177]. They also have better safety profiles due to their better immunocompatibility. In addition, they can bypass the endothelial layers in the blood–brain barrier or blood-retinal barrier, providing an ideal cargo to deliver biomolecules to the central nervous system [178].

Several studies have demonstrated the clinical effectiveness of MSC-EVs. For example, hBMMSC-EVs revealed significant improvements in patients suffering from refractory graft-versus-host disease [179]. In another study, administration of hUCMSC-EVs resulted in overall improvement in patients with grade III-IV chronic kidney disease [180]. Nassar et al. conducted a clinical trial to assess the effects of hUCMSC-EVs on pancreatic islet beta cell mass in Type-1 diabetic patients (NCT02138331). And there are other ongoing trials conducted to determine the safety and efficacy of human MSC-EVs in ocular diseases such as promoting the healing of large and refractory macular holes (NCT03437759) and relieving dry eye symptoms in oGVHD patients (NCT04213248). Moreover, MSC-EVs have been modified to load small molecules. For example, miR-124 was loaded in exosomes to treat patients with acute ischemic stroke (NCT03384433).

Digital technology and AI are driving the revolution of healthcare industry [181]. The drug research and development became an important application field of AI technology [182]. AI in de novo design has successfully produced biologically active molecules with desired properties [183]. The discovery of drug molecules by AI has been selected as one of the "top ten global breakthrough technologies" by MIT Technology Review in 2020. The advances of AI are likewise expected to boost the understanding of MSCs therapies and help identifying the essential elements of MSCs.

AI can find new molecular compounds and emerging drug targets much faster than traditional methods, thus speeding up the progress of drug development [184, 185]. At the same time, AI can more accurately predict the follow-up experimental results of new drugs, so as to improve the accuracy at each stage of drug development [186]. Computer-aided drug design techniques are thus revolutionizing MSCs therapies.

To understand the essential elements in MSCs treatment, AI may recognize the dynamic molecular characteristics of essential elements, which include different protein sequences, molecular structures, as well as the binding forces and stabilities between targeted molecules and cell receptors. These data could be used to train a predictive model to the utmost accuracy [187]. Predicted elements may also be produced under AI guidance. Powered by a robotic platform, a system developed by MIT researchers partially automates the production of small molecules that could be used in medicine, solar energy, and polymer chemistry. Reportedly, the new system combines three main steps. First, software guided by AI proposes a route for synthesizing a molecule, then chemical experts review this route and refine it into a chemical "recipe," and lastly, the recipe is sent to a robotic platform that automatically assembles the hardware and performs the reactions that build the molecule [188].

At present, the pharmaceutical world is increasingly engaged in technologies to shorten the time required to identify new drugs and repurpose current drugs. Since MSC therapies showed beneficial effects with complex undetermined components, AI may be well-suited to analyzing and revealing essential elements. Companies such as Merck, GSK, and Roche have developed partnerships with AI companies to construct suitable platforms [189, 190]. However, the drug discovery process with AI is a long shot, which need to be verified in clinical trials.

Paracrine effect was discovered to mediate MSCs therapeutic efficacy in previous studies [191‐193]. EVs are one of the major paracrine effectors, which are bilayer membrane structures transferring bioactive components [194]. The best-studied EVs can be classified into exosomes and microvesicles according to their sizes, shapes, biogenesis, origins, and compositions [195, 196]. Due to their liposome-like structures reflecting biophysical characteristics of the parental cells, EVs are stable in vivo compared to other foreign particles [197]. Moreover, it is relatively easy to modify and/or improve the contents of EVs and their surface properties to enhance the therapeutic potential or to act as a drug delivery system [198]. These advantages make EVs promising for clinical treatment. Currently, there are 15 clinical trials registered in ClinicalTrial.gov (Table 7). However, none has been completed and challenges remained for the practical application of EVs.

First of all, the manufacture of large scales of MSC-EVs with high purity is difficult. MSC-EVs are isolated from MSC culture media, of which conditions including the seeding cell number, media volume, and isolation method and time of EVs can influence both the quantity and quality of EVs [199]. Therefore, optimization of culture methods (e.g., hypoxia, sheer stress, and bioreactor) combining with intensive evaluation of the pros and cons of the different EVs isolation methods is prerequisites for MSC-EVs to yield improvements. These procedures should be regulated and controlled to ensure the clinical-grade EVs production [200]. Recently, Mendt et al. reported using a bioreactor system in the GMP facility to obtain sterile, clinical-grade EVs from BM-MSCs. In that instance, the therapeutic effects of BM-MSCs on pancreatic cancer xenograft mouse models were evaluated, and feasible directions for clinical application of MSC-EVs were provided [201].

Safety and efficacy of MSC-EVs in various disease conditions need to be ensured in further preclinical and clinical evaluation. In vivo distribution analysis of fluorescence-labeled EVs has shown that MSC-EVs might have homing capacity for injured or tumor-bearing sites comparable as MSCs [202]. Long-term toxicity and immunogenicity of repetitive EVs administration using hematological examination, histopathological analysis, and immunotyping test should also be performed to find whether MSC-EVs might trigger immune responses or toxic reactions [203].

After the disclosure of precise mechanisms of action or key therapeutic factors in MSC-EVs therapy, targeted-EVs could be expanded in uniform proliferative cells such as fibroblasts via gene modification technology. Therefore, with big data-based analysis of transcriptome and proteome, engineered EVs may be manufactured with desired elements. For instance, Thomas C. Roberts et al. engineered EVs to express IL6 signal transducer (IL6ST) decoy receptors to selectively inhibit the IL6 trans-signaling pathway. Treatment in the Duchenne muscular dystrophy mouse model with these IL6ST decoy receptor EVs resulted in a reduced phosphorylation of STAT3 in muscles; further functional studies verified the in vivo activity of the decoy receptor EVs as a potential therapy [204]. Similarly, CXCR4/TRAIL-enriched exosomes were successfully obtained from MSCs overexpressing both CXCR4 and TRAIL. These exosomes exerted activity as a cooperative agent with carboplatin against brain metastasis of breast cancer in vivo, improving the efficacy of chemotherapy and highlighting a novel synergistic protocol with anticancer agents to treat brain diseases [205, 206]. Moreover, in a Phase 1 clinical trial, IL-12 was engineered to express on the exosome surface using Codiak’s proprietary engEx Platform. This product could enhance the dose control of IL-12 and limit systemic exposure and associated toxicity. EVs can overcome the reported limitations of parental cells on various aspects, including safety, reproducibility, and cost-effectiveness related to storage and maintenance. Engineered EVs might be novel promising therapeutics for clinical application. Furthermore, to resolve current hurdles in EVs-based therapeutics, the production of EVs should be standardized and optimized, and its underlying mechanisms need further investigation.

Pandemic diseases like 2019 novel coronavirus disease (COVID-19) have dramatically increased the number of sickness and death worldwide. Though vaccines have been developed recently, the viruses are still rapidly mutating and expanding, and the available specific and effective treatment options are currently very limited [207]. For severe or critical COVID-19 patients requiring hospitalization, acute lung injures (ALI)/acute respiratory distress syndrome (ARDS) was the main pathologic features, characterized by immunopathological complications with cellular fibromyxoid exudates, extensive pulmonary inflammation, pulmonary edema, and hyaline membrane formation [208]. Besides, inflammation and sepsis are also the leading causes of mortality in COVID-19 patients [209]. In all these cases, any treatment that could hasten recovery would be in substantial demand. MSC therapy may be one such treatment.

MSC therapeutics may be the ideal candidates for handling the broad spectrum of COVID-19 symptoms due to their multifactorial mode-of-action [210]. They can release various factors including keratinocyte growth factor, prostaglandin E2, granulocyte–macrophage colony-stimulating factor (GM-CSF), IL-6, and IL-13 to facilitate the phagocytosis and alternative activation of alveolar macrophages, alter the cytokine secretion profile of dendritic cell subsets, and decrease the release of interferon γ from natural killer cells [211]. For example, IL-10, TGF-β, and tryptophan catabolizing enzyme indoleamine 2,3-dioxygenase secreted from them were reported to suppress the proliferation of T cells and change the cytokine secretion profile of T cell subsets [212]. Moreover, the proliferation, differentiation, and chemotactic properties of B cells were impaired by MSCs as well. Except for the immune regulatory effects, MSCs can enhance the restoration of capillary barriers, inhibit bacterial growth, and restore alveolar ATP. All these functions mentioned above might also be effective in COVID-19 infection.

COVID-19 has been the top priority of global healthcare systems since its emergence. There have been more than 160 vaccines in development and more than 60 clinical trials are ongoing, and now, only a few vaccines have been approved [213]. The representative clinical trials of MSC therapy in COVID-19 disease were listed in Table 8. But the rapid mutation of SARS-CoV-2 virus leads to challenges on the effect of the available vaccine. It is an urgent need to develop more universal and stable therapy to reverse or combat. Though no evidence has showed that coronavirus was eliminated completely after stem cell treatments, preliminary results were promising. Diseased patients were more likely to survive the infection after the treatment. The specific primed MSCs were also investigated for COVID-19 treatment [212, 214]. The results will provide a strong foundation for future scientific research and clinical applications for a variety of diseases including pandemic crisis and pulmonary complications. Hopefully, the approaches utilizing MSCs particularly the primed MSCs could be vital for the success of cell therapy in treating COVID-19.